NASDAQ:PALI

Palisade Bio Stock Insider Trading

Healthcare > Biotechnology

Buy PALI

*Your capital is at risk

$1.93

+0.0700 (+3.76%)

At Close: Jun 03, 2026

Palisade Bio Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.67. In total, the insiders bought 43.73M and sold 12.76K PALI shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.67
● Buy	43.73M shares
● Sell	12.76K shares
84% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Sep 04, 2025 Buy	Phantom Units A-Award	Wei Binxian Director	Director	18 800 Value: $11.9K
Sep 04, 2025 Buy	Phantom Units A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	289 000 Value: $182.9K
Sep 04, 2025 Buy	Phantom Units A-Award	Chuang Emil Director	Director	18 800 Value: $11.9K
Sep 04, 2025 Buy	Phantom Units A-Award	Chuang Emil Director	Director	18 800 Value: $11.9K
Sep 04, 2025 Buy	Phantom Units A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	289 000 Value: $182.9K
Sep 04, 2025 Buy	Phantom Units A-Award	Wei Binxian Director	Director	18 800 Value: $11.9K
Sep 04, 2025 Buy	Phantom Units A-Award	Finley John David CEO, CFO	CEO / President	323 400 Value: $204.6K
Sep 04, 2025 Buy	Phantom Units A-Award	Williams Donald Allen Director	Director	64 400 Value: $40.7K
Jul 07, 2025 Buy	Common Stock J-Other	Chuang Emil	Director	0 Value: $0
Jul 07, 2025 Buy	Common Stock J-Other	Chuang Emil	Director	0 Value: $0
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	29 000 Value: $32.8K
Feb 11, 2025 Buy	Restricted Stock Units A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	24 000 Value: $27.1K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Finley John David CEO, CFO	CEO / President	47 000 Value: $53.1K
Feb 11, 2025 Buy	Restricted Stock Units A-Award	Finley John David CEO, CFO	CEO / President	40 000 Value: $45.2K
Feb 11, 2025 Buy	Restricted Stock Units A-Award	Finley John David CEO, CFO	CEO / President	40 000 Value: $45.2K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Finley John David CEO, CFO	CEO / President	47 000 Value: $53.1K
Feb 11, 2025 Buy	Restricted Stock Units A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	24 000 Value: $27.1K
Feb 11, 2025 Buy	Stock Option (Right to Buy) A-Award	Jones Mitchell Lawrence Chief Medical Officer	Officer	29 000 Value: $32.8K
Nov 21, 2024 Buy	Comon Stock, par value $0.01 M-Exempt	Wei Binxian Director	Director	388 Value: $947
Nov 21, 2024 Buy	Comon Stock, par value $0.01 M-Exempt	Williams Donald Allen Director	Director	388 Value: $947
Nov 21, 2024 Buy	Comon Stock, par value $0.01 M-Exempt	Williams Donald Allen Director	Director	388 Value: $947
Nov 21, 2024 Buy	Comon Stock, par value $0.01 M-Exempt	Wei Binxian Director	Director	388 Value: $947
Jul 11, 2024 Buy	Common Stock Options A-Award	Wei Binxian Director	Director	2 100 Value: $9K
Jul 11, 2024 Buy	Common Stock Options A-Award	Fischbein Margery B. Director	Director	2 100 Value: $9K
Jul 11, 2024 Buy	Common Stock Options A-Award	Williams Donald Allen Director	Director	2 100 Value: $9K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PALISADE BIO, INC.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor that is intended to inhibit digestive enzyme activity and preserve gut integrity during int...

Read Full Profile Here